PATENT CLAIM ANALYSIS

Application Number: 15879260
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "136100"]

Abstract:
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Claim (Index 5):
A method of inducing lysis of a target cell, comprising contacting a target cell with a T cell activating bispecific antigen-binding molecule in the presence of a T cell, the T cell activating bispecific antigen-binding molecule comprising:\n (a) a first Fab molecule which specifically binds to a first antigen; and (b) a second Fab molecule which specifically binds to a second antigen, wherein the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other, wherein the first antigen is an activating T cell antigen and the second antigen is a target cell antigen, or the first antigen is a target cell antigen and the second antigen is an activating T cell antigen, and wherein:\n (i) in the constant domain CL of the first Fab molecule under (a) the amino acid at position 124 is substituted independently by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat), and wherein in the constant domain CH1 of the first Fab molecule under (a) the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index); or \n (ii) in the constant domain CL of the second Fab molecule under (b) the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and wherein in the constant domain CH1 of the second Fab molecule under (b) the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to Kabat EU index).

Metadata:
- Claim Count in Document: 15.0
- Percentile: 86.0
- Lexical Diversity: 2.0
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15879040', '14816252', '15501620', '15747385', '14188486']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.813157297594588
- 35 USC 102 Novelty (BERT): 0.7050501029944656
- Combined Prediction Score: 0.8023465781345758
- Mean Citation Score: 678.8108719999999
- Max Citation Score: 861.5915
- Similarity Product: 716.4422910474836

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test